公开(公告)号：US20230220074A1

公开(公告)日：2023-07-13

申请号：US17904513

申请日：2021-02-17

Applicant: Alector LLC

Inventor： Spencer LIANG ,  Samuel NALLE ,  Ling LEUNG

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2039/507

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.

公开(公告)号：US20240425587A1

公开(公告)日：2024-12-26

申请号：US18686156

申请日：2022-08-24

Applicant: ALECTOR LLC

Inventor： Samuel NALLE ,  Spencer LIANG ,  Ling LEUNG ,  Yong WANG ,  Angie Grace YEE

IPC: C07K16/28

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PILRA and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PILRA block binding of PILRA to ligand, block binding of soluble PILRA to T cells, and/or decrease cell surface PILRA. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with myeloid cell dysfunction.